--- title: "Subscribers" description: "CBRNe World provides those tasked with defending against CBRN and IED threats with the essential practical, scientific and political information. Access the current and previous issues of the magazine by registering as a member." url: "https://cbrneworld.com/news/subscribers?start=871" date: "2026-07-31T09:03:48+00:00" language: "en-GB" --- [![](https://cbrneworld.com/images/News-Images/Bavarian_Nordic_Logo.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1646:bavarian-nordic-to-manufacture-additional-ebola-vaccines-for-janssen&catid=12) ## [Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen](https://cbrneworld.com/index.php?option=com_content&view=article&id=1646:bavarian-nordic-to-manufacture-additional-ebola-vaccines-for-janssen&catid=12) Written by Gwyn Winfield on 16 June 2020. Bavarian Nordic announced today this month that the Company has entered into a new supply contract with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson valued at USD 13.9 million. Under the contract, Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN® Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen. While manufacturing of the vaccines will be initiated in 2020, supply and invoicing will not occur until 2021. Hence the contract does not impact the Company’s financial guidance for the full year 2020. “We are pleased to continue our strong collaboration with Janssen,” said Paul Chaplin, President & CEO of Bavarian Nordic. “Ebola remains a significant threat to global health security, and the supply of vaccines for local citizens, healthcare workers and others who are being deployed in risk areas is crucial to prevent future outbreaks.” The contract builds on Bavarian Nordic’s existing collaboration with Janssen, under which Bavarian Nordic has previously manufactured more than 2 million doses of MVA-BN Filo. In May 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion, recommending approval of the Ebola vaccine regimen which consists of two components, Ad26.ZEBOV, which is given first, and MVA-BN Filo which is administered approximately eight weeks later as a second vaccination. The final approval is pending decision by the European Commission. [Threat](https://cbrneworld.com/component/tags/tag/threat), [Protection](https://cbrneworld.com/component/tags/tag/protection), [Biological](https://cbrneworld.com/component/tags/tag/biological) [![](https://cbrneworld.com/templates/yootheme/cache/47/DHS_ST-47bed3b1.png)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1645:dhs-s-t-launch-online-sars-cov-2-airborne-decay-calulator&catid=12) ## [DHS S&T Launch Online SARS-CoV-2 Airborne Decay Calulator](https://cbrneworld.com/index.php?option=com_content&view=article&id=1645:dhs-s-t-launch-online-sars-cov-2-airborne-decay-calulator&catid=12) Written by Gwyn Winfield on 16 June 2020. The Department of Homeland Security Science and Technology Directorate (S&T) added an online calculator last week that estimates the natural decay of SARS-CoV-2 in the air. The calculator is based on research still underway at S&T’s National Biodefense Analysis and Countermeasures Center in Maryland. “This groundbreaking research into how COVID-19 spreads and the new interactive model from DHS S&T will have far-reaching impact,” William Bryan, DHS Senior Official performing the duties of the Under Secretary for Science & Technology. “The easily accessible tool allows officials, the medical community, and individuals to make more informed decisions to protect their own health and well-being.” Dubbed the airborne predictive model, the tool builds on a previous S&T tool that modeled the survival of SARS-CoV-2 on non-porous surfaces indoors. The predictive model evaluates and factors in the impact of conditions such as temperature, ranging from 50 to 86 degrees Fahrenheit; humidity, ranging from 20 to 70 percent; and sunlight, charting the effects of an ultraviolet index up to 10. This tool goes to show how much more we have learned about SARS-CoV-2 in the past couple of months, and it is a fascinting tool to play with, even if you aren't scienfitically minded. Head to their website to check it out both the airborne [](https://www.dhs.gov/science-and-technology/sars-airborne-calculator) and surface decay [](https://www.dhs.gov/science-and-technology/sars-calculator) calculators [Threat](https://cbrneworld.com/component/tags/tag/threat), [Protection](https://cbrneworld.com/component/tags/tag/protection), [Biological](https://cbrneworld.com/component/tags/tag/biological) [![](https://cbrneworld.com/templates/yootheme/cache/7d/FDA_Logo-7dbc03a4.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1644:fda-revokes-eua-for-hydroxychloroquine-to-treat-coronavirus&catid=12) ## [FDA revokes EUA for Hydroxychloroquine to treat Coronavirus](https://cbrneworld.com/index.php?option=com_content&view=article&id=1644:fda-revokes-eua-for-hydroxychloroquine-to-treat-coronavirus&catid=12) Written by Gwyn Winfield on 16 June 2020. It was announced on June 15th that the US Food and Drug Adminsitration (FDA) had revoked the Emergency Use Autorisation of oral formulations of chloroquine phosphate and hydroxychloroquine sulfate for the treatment of COVID-19. A request was submitted to the FDA by BARDA stating that they were requesting to revoke the use of these drugs "based on new information, including clinical trial data results, that have led BARDA to conclude that this drug may not be effective to treat COVID-19 \[Coronavirus Disease 2019\] and that the drug’s potential benefits for such use do not outweigh its known and potential risks" Upon review of the data, and regulations the FDA also concluded that "it is no longer reasonable to believe that oral formulations of HCQ and CQ may be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks. Accordingly, FDA revokes the EUA for emergency use of HCQ and CQ to treat COVID-19, pursuant to section 564(g)(2) of the Act. As of the date of this letter, the oral formulations of HCQ and CQ are no longer authorized by FDA to treat COVID-19." The full letter outling the revocation can be viewed [here](https://www.fda.gov/media/138945/download) [Biological](https://cbrneworld.com/component/tags/tag/biological) [![](https://cbrneworld.com/images/News-Images/START-logo.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1643:start-developing-tools-to-identify-potential-cbrn-threats&catid=12) ## [START developing tools to identify potential CBRN threats](https://cbrneworld.com/index.php?option=com_content&view=article&id=1643:start-developing-tools-to-identify-potential-cbrn-threats&catid=12) Written by Gwyn Winfield on 16 June 2020. The National Consortium for the Study of Terrorism and Responses to Terrorism (START) is creating a process to identify potential CBRN threats from non-state actors. Advancing U.S. CWMD/CWMT Capabilities in Support of the SIGMA+ Program through Development of Anticipatory Human Social Systems Models and Adversary Weapon Selection Decision Processes, the project will support DARPA's SIGMA+ Program and run from March 2020 to March 2022. “This project expands upon previous work in which we sought to understand the behaviors of violent non-state actors in terms of their motivation to conduct a CBRN attack,” START Assistant Research Scientist Thomas Guarrieri said. “Now, we’re trying to automate a process by which we can quickly identify threats from adversaries who might conduct CBRN attacks, given what we know about the motivations of CBRN adversaries.” This research effort will provide the U.S. government first of-its-kind adversary social systems models in support of the Defense Advanced Research Projects Agency’s SIGMA+ Program. Results of this research effort, in addition to contributing to the success of the SIGMA+ Program, will also contribute greatly to the advancement of the U.S. government’s overall capability to defend against weapons of mass destruction/weapons of mass terror (WMD/WMT) threats. The research will result in several products that will become integral components of the SIGMA+ system, including an Adversary Weapon Selection Dataset (AWSD), an Adversary Automated Template Generation Tool (AATG Tool) and a Geospatial Risk Mapping Tool. For more information on this project, and the other work START are doing click [here](https://www.start.umd.edu/) [Threat](https://cbrneworld.com/component/tags/tag/threat), [CBRNe](https://cbrneworld.com/component/tags/tag/cbrne), [R&D](https://cbrneworld.com/component/tags/tag/r-d) [![](https://cbrneworld.com/images/News-Images/SIGA-Technologies-Inc.-logo.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1642:siga-technologies-announces-dod-increases-funding-to-develop-post-exposure-prophylactic-indication-for-tpoxx&catid=12) ## [SIGA Technologies Announces DOD Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX®](https://cbrneworld.com/index.php?option=com_content&view=article&id=1642:siga-technologies-announces-dod-increases-funding-to-develop-post-exposure-prophylactic-indication-for-tpoxx&catid=12) Written by Gwyn Winfield on 15 June 2020. SIGA Technologies, Inc. (SIGA) today announced that the United States Department of Defense (DoD), via the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), has increased research and development funding to approximately $23 million in connection with the DoD contract to support work necessary to gain a potential label expansion from the U.S. Food and Drug Administration (FDA) for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox. The use of TPOXX for PEP could provide significant potential benefit in the event of a smallpox pandemic or outbreak. While vaccines would play an important role in containing the spread of smallpox, they are only effective if administered prior to infection or no later than four days after infection. However, symptoms of smallpox do not typically appear until approximately 14 days post-infection, and there is currently no diagnostic test to determine infection prior to symptom onset. Given the uncertainty of an individual’s infection status in that two-week period, and the highly contagious nature of smallpox, the administration of a vaccine in combination with TPOXX could be an important strategy for reducing morbidity and mortality in a smallpox outbreak. Dosing of TPOXX in the PEP indication is expected to be 28 days rather than the 14-day dosing currently recommended for its use in treating patients with active smallpox infections. This would increase the amount of TPOXX used for each exposed person compared with each infected person. “During our FDA Advisory Committee meeting in May 2018, several committee members emphasized the importance of evaluating the potential use of TPOXX not only to treat smallpox symptomatic infection, but also to treat patients with known smallpox exposure who have not yet developed symptoms,” said Dr. Phil Gomez, CEO of SIGA. “An expansion of the TPOXX label to include its use for PEP would provide greater flexibility to deliver TPOXX to those who might benefit from treatment during a potential outbreak. The recent search for prophylactic agents that could be used for PEP in patients with known exposure to the virus that causes COVID-19 underscores the importance of being able to prevent infection in at-risk individuals. We are pleased to be working with DoD on important studies for a PEP indication that could address similar situations that would arise in the event of a smallpox outbreak.” [Threat](https://cbrneworld.com/component/tags/tag/threat), [Protection](https://cbrneworld.com/component/tags/tag/protection), [Biological](https://cbrneworld.com/component/tags/tag/biological) [![](https://cbrneworld.com/templates/yootheme/cache/e0/Mosquito-e0beeb3d.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1641:vaccine-made-from-mosquito-spit-could-help-prevent-epidemics&catid=12) ## [Vaccine made from mosquito spit could help prevent epidemics](https://cbrneworld.com/index.php?option=com_content&view=article&id=1641:vaccine-made-from-mosquito-spit-could-help-prevent-epidemics&catid=12) Written by Gwyn Winfield on 15 June 2020. In a new study published this week in *The Lancet,* NIAID scientists describe the results of a small Phase 1 trial of a vaccine designed to provide broad protection against mosquito-borne diseases. The trial indicated that the vaccine is safe and induces a strong immune response in healthy volunteers. [Threat](https://cbrneworld.com/component/tags/tag/threat), [Protection](https://cbrneworld.com/component/tags/tag/protection), [Biological](https://cbrneworld.com/component/tags/tag/biological) [Read more …Vaccine made from mosquito spit could help prevent epidemics](https://cbrneworld.com/index.php?option=com_content&view=article&id=1641:vaccine-made-from-mosquito-spit-could-help-prevent-epidemics&catid=12) [![](https://cbrneworld.com/templates/yootheme/cache/26/IAEA_Logo-2628bf99.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1640:iaea-launches-initiative-to-help-prevent-future-pandemics&catid=12) ## [IAEA Launches Initiative to Help Prevent Future Pandemics](https://cbrneworld.com/index.php?option=com_content&view=article&id=1640:iaea-launches-initiative-to-help-prevent-future-pandemics&catid=12) Written by Gwyn Winfield on 15 June 2020. The Director General of the International Atomic Energy Agency (IAEA), Rafael Mariano Grossi, launched an initiative today to strengthen global preparedness for future pandemics like COVID-19. The project, called ZODIAC, builds on the IAEA’s experience in assisting countries in the use of nuclear and nuclear-derived techniques for the rapid detection of pathogens that cause transboundary animal diseases, including ones that spread to humans. These zoonotic diseases kill around 2.7 million people every year. The IAEA Zoonotic Disease Integrated Action (ZODIAC) project will establish a global network to help national laboratories in monitoring, surveillance, early detection and control of animal and zoonotic diseases such as COVID-19, Ebola, avian influenza and Zika. ZODIAC is based on the technical, scientific and laboratory capacity of the IAEA and its partners and the Agency’s mechanisms to quickly deliver equipment and know-how to countries. The aim is to make the world better prepared for future outbreaks. “Member States will have access to equipment, technology packages, expertise, guidance and training. Decision-makers will receive up-to-date, user-friendly information that will enable them to act quickly,” Mr Grossi told a meeting of the IAEA Board of Governors. Mr Grossi said COVID-19 had exposed problems related to virus detection capabilities in many countries, as well as a need for better communication between health institutions around the world. While the IAEA has been doing important work to help countries in these areas, such as through the provision of COVID-19 tests, he said it was “essential to pull these diverse strands together into a coherent and comprehensive framework of assistance”. Nuclear-derived techniques, such as tests using real time reverse transcription–polymerase chain reaction ([RT-PCR](https://www.iaea.org/newscenter/news/how-is-the-covid-19-virus-detected-using-real-time-rt-pcr)), are important tools in the detection and characterization of viruses. The IAEA is providing emergency assistance to some [120 countries](https://www.iaea.org/newscenter/pressreleases/dozens-of-countries-receive-covid-19-testing-equipment-from-the-iaea) in the use of such tests to rapidly detect COVID-19. Zoonotic diseases are caused by bacteria, parasites, fungi or viruses that originate in animals and can be transmitted to humans. Many of these diseases are treatable if medication is available, such as E. coli- and brucella bacterial infections. But others have the potential to severely affect humans, such as Ebola, SARS and COVID-19. ZODIAC builds on the experience of VETLAB, a network of veterinary laboratories in Africa and Asia that was originally set up by the Food and Agriculture Organization of the United Nations (FAO) and the IAEA to combat the cattle disease rinderpest. VETLAB now supports countries in the early detection of several zoonotic and animal diseases, such as African swine fever and pest des petit ruminants (PPR). “About 70 per cent of all diseases in humans come from animals,” said Gerrit Viljoen, Head of the Animal Production and Health Section of the Joint FAO/IAEA Programme for Nuclear Techniques in Food and Agriculture. ZODIAC aims to help veterinary and public health officials identify these diseases before they spread. “We have seen an increase in the number of zoonotic epidemics in the last decades: first Ebola, then Zika, and now COVID-19. It’s important to monitor what is in the animal kingdom – both wildlife and livestock – and to act quickly on those findings before the pathogens jump to humans,” Mr Viljoen said. Following the One Health concept for a multidisciplinary collaborative approach between human and animal health authorities and specialists, ZODIAC will benefit from the unique joint FAO/IAEA laboratories and from partners such as the World Health Organization (WHO) and the World Organisation for Animal Health (OIE). “We have a unique capacity to provide laboratory support and guidance to countries,” said Mr Viljoen, adding that ZODIAC will, for example, provide technical know-how and advice to laboratories on test performance and assist authorities in the interpretation of results and in devising containment measures. ZODIAC will also support R&D activities for novel technologies and methodologies for early detection and surveillance. Under the project, the IAEA will enhance its capacities to host scientists and fellows from Member States at its Seibersdorf laboratories outside Vienna and to carry out research on immunological, molecular, nuclear and isotopic tests, as well as in the use of irradiation to develop vaccines against diseases such as avian influenza. [Threat](https://cbrneworld.com/component/tags/tag/threat), [Protection](https://cbrneworld.com/component/tags/tag/protection), [Biological](https://cbrneworld.com/component/tags/tag/biological) [![](https://cbrneworld.com/templates/yootheme/cache/01/House-of-Lords-Science-01e793d9.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1639:covid-19-inquiry-lords-committee-to-tackle-immunology-and-pathophysiology&catid=12) ## [COVID-19 Inquiry: Lords committee to tackle immunology and pathophysiology ](https://cbrneworld.com/index.php?option=com_content&view=article&id=1639:covid-19-inquiry-lords-committee-to-tackle-immunology-and-pathophysiology&catid=12) Written by Gwyn Winfield on 12 June 2020. The House of Lords Science and Technology Committee will next week continue its inquiry into the science of COVID-19. The committee will hear from further leading academics and medical professionals on the immune response to the virus, before continuing with a more detailed look at the effects of the disease within the human body. Both evidence sessions will be conducted on zoom and can be followed at [www.parliamentlive.tv](https://u7061146.ct.sendgrid.net/ls/click?upn=4tNED-2FM8iDZJQyQ53jATUU4UPBBIPgh4ms-2BCwrl0zDMkqW4TVntVR9haW81V8QGJW61ieDOloRVmzQP33TP73Ba-2FkegtoxrvmwtP0jb6H9oB10N10jQ33Y-2BonmiwpdIOVaTE_1LyHAZHVVXJjX-2FphpLvBOT0Qxou-2FpaYZ8ZCYYgmBywKWCjO6VWcqIsjfjbl4rhzYzZ9cXqu2LLHhL-2FvBAyooAKbMxbpnPhnuHedmUMSHoNqd7s1w4tkyoQt5MR-2FkdrsxDiu7fBpkZY0wNqrE4EVtjFdrBP5BQYCo4rBcGz779-2Fy5HRps9ou0N0HZqxWe2JXoOIpiZSDhek7a-2FQviad-2Fa-2FyIqPw0RVJvOuzhiZFj92xmR-2FgG9k2AXoPAd7j0knzSUXI-2F6ARIzvGkNrsIyM3cjrmp6IPt5d1Egqq6o0Ik9HqyIJOYUINARdMW3EbcuF9DTihzUXaskExt8MFCYdKvRc7WbhGcGXPxJTb-2BgI25euX0-3D) from 3pm (GMT) on Monday 15 June. **3pm: Immunology** Giving evidence will be: - **Professor Sir John Bell,** Regius Professor of Medicine, University of Oxford - **Professor Adrian Hayday,** Chair in the Department of Immunobiology, Kings College London; and Group Leader, Immunosurveillance Laboratory, Francis Crick Institute - **Professor Massimo Palmarini,** Chair of Virology and Director of MRC-University of Glasgow Centre for Virus Research, University of Glasgow Questions will include: - What are the key elements of the human immune response to a novel pathogen such as SARS-CoV-2? - How much variation is there between individuals' immune responses to the virus? - In what ways does the immune response vary by age, and why? - What is a cytokine storm, and why does it occur? - What constitutes "effective immunity" against reinfection by SARS-CoV-2? - To what extent do we understand the relative role of antibodies and T-cells in conferring SARS-CoV-2 immunity? - Is there any evidence that exposure to other coronaviruses confers any immunity to this novel virus? - To what extent are COVID-19 treatment strategies focusing on modulating the immune response to the virus? **4pm: Pathophysiology** Giving evidence will be: - **Professor Mauro Giacca**, Professor of Cardiovascular Sciences, King's College London - **Professor Beverley Hunt OBE**, Consultant in Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust - **Dr Manu Shankar-Hari**, NIHR Clinician Scientist, Reader and Consultant in Intensive Care Medicine, King's College London - **Dr Elizabeth Whittaker**, Consultant in Paediatric Infectious Diseases, St Mary's Hospital; and Lecturer in Paediatric Infection and Immunity, Imperial College Questions will include: - Please give us a brief overview of how the SARS-CoV-2 virus causes COVID-19 disease in humans? - What is the natural progression of the disease and how quickly does the disease progress in the body? - What factors appear to account for variation in disease susceptibility and disease severity between individuals? - Why do some categories of people appear more susceptible to severe forms of the disease? - What is our understanding of why some people experience less severe disease? - To what extent do we understand the possible role of genetics in determining the susceptibility to infection, and to severity of disease? - To what extent do we understand the long-term health consequences of COVID-19 infection? [Threat](https://cbrneworld.com/component/tags/tag/threat), [Biological](https://cbrneworld.com/component/tags/tag/biological) [![](https://cbrneworld.com/images/events/sponsor_logos/emergent_logo_PMS1925_registered.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1638:emergent-biosolutions-signs-agreement-to-be-u-s-manufacturing-partner-for-astrazeneca-s-covid-19-vaccine-candidate&catid=12) ## [Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate](https://cbrneworld.com/index.php?option=com_content&view=article&id=1638:emergent-biosolutions-signs-agreement-to-be-u-s-manufacturing-partner-for-astrazeneca-s-covid-19-vaccine-candidate&catid=12) Written by Gwyn Winfield on 12 June 2020. Emergent BioSolutions Inc. announced on June 11th it will deploy its molecule-to-market contract development and manufacturing (CDMO) services to support the manufacturing of AstraZeneca’s vaccine candidate for COVID-19, AZD1222, a viral vector-based, weakened version of adenovirus containing the genetic material of SARS-CoV-2 spike protein, developed by Oxford University’s Jenner institute working with the Oxford Vaccine Group. AstraZeneca’s AZD1222 is one of several candidates supported by Operation Warp Speed (OWS), the U.S. government’s program to accelerate the development, manufacturing, and distribution of COVID-19 medical countermeasures that aims to have substantial quantities of a safe and effective vaccine available for Americans by January 2021. As part of OWS, Emergent will provide development and manufacturing services and capacity to innovators of leading COVID-19 vaccine candidates selected by the U.S. government, such as AstraZeneca. “By partnering with leading innovators like AstraZeneca, Emergent is playing a critical role in increasing the world’s chances of having a safe and effective COVID-19 vaccine,” said Robert G. Kramer Sr., president and chief executive officer of Emergent BioSolutions. “We are proud to provide our CDMO services to advance AstraZeneca’s COVID-19 vaccine candidate. With this agreement, we bring to our facilities two of the five leading candidates being developed with U.S. government funding." Under the agreement, valued at approximately $87 million, Emergent will provide development services, technology transfer, analytical testing, drug substance process and performance qualification and will reserve certain large-scale manufacturing capacity through 2020. “As both a manufacturer of our own vaccines and a service provider, Emergent is uniquely equipped to take on the integral role of development and manufacturing partner to companies like AstraZeneca with lead vaccine candidates for COVID-19,” said Syed T. Husain, senior vice president and CDMO business unit head at Emergent. “We have spent decades establishing a strong, integrated CDMO network that allows us to dependably and consistently produce life-saving medicines for our company and for others worldwide.” Development services will be provided out of Emergent’s Gaithersburg product development facility. Large-scale manufacturing of drug substance will be done at the Baltimore Bayview facility, an HHS-designated Center for Innovation in Advanced Development and Manufacturing (CIADM) designed for rapid manufacturing of large quantities of vaccines and treatments during public health emergencies. Emergent’s Bayview facility has unique capabilities across four independent suites to produce at clinical scale to get candidates rapidly into the clinic, while at the same time scaling up to enable large-scale manufacturing to up to 4000L to prepare for production of commercial volumes to meet customer demand. The CIADM has the capacity to produce tens to hundreds of millions of doses of vaccine on an annual basis, based upon the platform technology being used. **Financial Considerations** The company will provide an update to its 2020 financial outlook incorporating expectations related to this agreement and any other relevant information when it reports its second quarter financial results. [Threat](https://cbrneworld.com/component/tags/tag/threat), [Protection](https://cbrneworld.com/component/tags/tag/protection), [Biological](https://cbrneworld.com/component/tags/tag/biological) [![](https://cbrneworld.com/images/events/sponsor_logos/bertin-instruments-COULEUR_vectorised_sans_baseline.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1637:evaluation-of-sars-cov-2-air-contamination-in-hospitals-with-coriolis-air-sampler&catid=12) ## [Evaluation of SARS-CoV-2 air contamination in hospitals with Coriolis μ air sampler](https://cbrneworld.com/index.php?option=com_content&view=article&id=1637:evaluation-of-sars-cov-2-air-contamination-in-hospitals-with-coriolis-air-sampler&catid=12) Written by Gwyn Winfield on 12 June 2020. The current pandemic of Covid-19 has shown the vulnerability of our healthcare systems when faced with viral infections without a known treatment Understanding the transmission behavior of SARS-CoV-2 in the air will be a crucial step to managing the current outbreak and design the appropriate prevention and control measures. In this document, we present how researchers in Imperial College have been evaluating SARS-CoV-2 surface and air contamination in a hospital during the peak of the COVID-19 pandemic in London, using surface swabs and the Coriolis μ air sampler coupled with RT qPCR and viral culture. To access the Imperial College paper [click here ](https://www.medrxiv.org/content/10.1101/2020.05.24.20110346v2.full.pdf) To find out more about the Coriolis and Bertin's range of air samplers [click here ](https://www.bertin-instruments.com/products-range/air-samplers/) [Detection](https://cbrneworld.com/component/tags/tag/detection), [Threat](https://cbrneworld.com/component/tags/tag/threat), [Equipment](https://cbrneworld.com/component/tags/tag/equipment), [Biological](https://cbrneworld.com/component/tags/tag/biological) [![](https://cbrneworld.com/templates/yootheme/cache/2d/Ebola-2dec8635.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1634:ebola-in-equateur-province-is-a-new-spillover-event&catid=12) ## [Ebola in Equateur Province is a New Spillover Event](https://cbrneworld.com/index.php?option=com_content&view=article&id=1634:ebola-in-equateur-province-is-a-new-spillover-event&catid=12) Written by Gwyn Winfield on 12 June 2020. On the same day that the 42 day countdown to the end of the Ebola epidemic was started in the Deomcratic Republic of Congo another outbreak began in Equateur Province. [Threat](https://cbrneworld.com/component/tags/tag/threat), [Biological](https://cbrneworld.com/component/tags/tag/biological) [Read more …Ebola in Equateur Province is a New Spillover Event](https://cbrneworld.com/index.php?option=com_content&view=article&id=1634:ebola-in-equateur-province-is-a-new-spillover-event&catid=12) [![](https://cbrneworld.com/images/News-Images/Blauer-Bio-99.jpeg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1633:blauer-manufacturing-receives-third-party-nfpa-1999-certification-for-reusable-covid-19-ppe&catid=12) ## [Blauer Manufacturing Receives Third-Party NFPA 1999 Certification for Reusable COVID-19 PPE](https://cbrneworld.com/index.php?option=com_content&view=article&id=1633:blauer-manufacturing-receives-third-party-nfpa-1999-certification-for-reusable-covid-19-ppe&catid=12) Written by Gwyn Winfield on 12 June 2020. Blauer Manufacturing announced on June 11th that it received formal 3rd party certification for its new BIO-99™ coverall to the NFPA 1999 *Standard on Protective Clothing and Ensembles for Emergency Medical Operations* for multiple-use ([](https://c212.net/c/link/?t=0&l=en&o=2827696-1&h=2618477046&u=https%3A%2F%2Fwww.blauer.com%2Fbio-99&a=https%3A%2F%2Fwww.blauer.com%2Fbio-99)). Safety Equipment Institute, a leading certification organization for safety and protective products, issued the certification letter for the BIO-99 coverall after extensive evaluations against rigorous viral penetration, durability, functionality, and comfort-related requirements. The certification marks the successful conclusion of an expedited development effort on the part of Blauer's design team and W. L. Gore & Associates to commercialize a reusable, breathable and highly protective coverall made with GORE® CROSSTECH® fabric suitable for Emergency Medical Service (EMS) and other frontline workers to wear for COVID-19 response. According to Tom Ames, Blauer's Vice President of Marketing & Business Development, "The BIO-99 is the first viral resistant coverall certified to the rigorous multi-use requirements of the NFPA 1999 Standard for First Responders. The innovative BIO-99 also meets The Interagency Board's (IAB) new *PPE Considerations for Dermal Protection* in the recently published *Minimum Recommended Guidance on Protection and Decontamination of First Responders Involved in COVID-19 Cases.* Blauer dedicated its product development team to designing and certifying a highly breathable, durable, and reusable NFPA 1999-certified coverall for first responders and frontline workers that offers much higher protection than disposable isolation gowns. The BIO-99 was specifically engineered to maintain its protective properties even after numerous uses and commercial launderings. The employees of Blauer Manufacturing are excited to introduce a new class of PPE that will enhance our nation's ability to respond to the current COVID-19 crisis as well as future pandemics." Blauer has begun production of the BIO-99 coverall and is fulfilling orders and quote requests from emergency medical, fire/HAZMAT and law enforcement teams around the country. For technical data, pricing and availability, please visit [](https://c212.net/c/link/?t=0&l=en&o=2827696-1&h=2618477046&u=https%3A%2F%2Fwww.blauer.com%2Fbio-99&a=https%3A%2F%2Fwww.blauer.com%2Fbio-99) . [Equipment](https://cbrneworld.com/component/tags/tag/equipment), [Protection](https://cbrneworld.com/component/tags/tag/protection), [Biological](https://cbrneworld.com/component/tags/tag/biological) [![](https://cbrneworld.com/templates/yootheme/cache/1c/Tiki-Mask-1c95dcac.jpeg)](https://cbrneworld.com/index.php?option=com_content&view=article&id=1632:innovative-papr-from-sweden&catid=12) ## [Innovative PAPR from Sweden](https://cbrneworld.com/index.php?option=com_content&view=article&id=1632:innovative-papr-from-sweden&catid=12) Written by Gwyn Winfield on 10 June 2020. The Tiki Respiratory Protection Mask Tiki was developed in Sweden, intended for use in demanding settings with the highest requirements of protection against airborne particles and bacteria. The Tiki mask is reusable, has self-adjusting ventilation and is operated with batteries. The mask measures the strength of every breath in real time and supplies the air and the pressure the user needs. A unique feature of the Tiki mask is that the motor and filter are on the top part of the mask instead of on a belt around the waist, providing better visibility and mobility.. And in contrast to other types of respirators where the filter is in front of the mouth and nose, the user’s face is visible in the Tiki mask, improving communication with co-workers and patients. Manufacturing is done in Tiki Safety's factories in Bro, north of Stockholm. - Lightest weight PAPR out there at less than 14 oz. - Attach the harness and you are ready to go right out of the box. - No cumbersome hoses to attach and wear - No belt to wear - Can be used with anyone's protective garment with hood that is appropriate for the particular hazard/job which is more versatile and less costly. The replacement costs for the 3M or Maxair hoods are expensive. The commercially available disposable hoods or hooded garments run about $8-$10 which makes them easily disposable in a highly contaminated environment where decon is not possible - Clear face piece so the patient and worker can see each other - No need for extra communication systems since speech isn't hindered by the face piece - Face piece passes the highest European eye protection standard- EN166F - The PAPR passes the highest European PAPR standard EN12942 TM3P which is a safety protection level of 2,000 - Workers want to use it since it is so light and easy - The replacement costs of the mask runs around $40 (distributor). Compare that with the competition - Takes up less space - in the case of an emergency situation 400 masks would only take up 1 cubic meter which saves on transportation costs. - Low battery warning so wearer knows to exit with about 15 minutes left - Leak warning - High level light weight battery available that has a clip to extend the time to 10 hours - Car charger available - not sure that the competition has this. - Three mask sizes - SM, MD, and LG. - Blower is breath responsive and matches the users breathing for maximum comfort. - Built in LED lighting - Lowest cost of ownership on the market. The whole unit is considerably less than the competition and the replacement parts are economical. If you would like information on purchasing the Tiki system please contact Brian Lyons at [](https://cbrneworld.com/javascript:/*%20This%20email%20address%20is%20being%20protected%20from%20spambots.*/) or [](https://cbrneworld.com/javascript:/*%20This%20email%20address%20is%20being%20protected%20from%20spambots.*/) See the Tiki in action [https://youtu.be/KVGRdXjYlAk ](https://youtu.be/KVGRdXjYlAk) [Threat](https://cbrneworld.com/component/tags/tag/threat), [Equipment](https://cbrneworld.com/component/tags/tag/equipment), [Protection](https://cbrneworld.com/component/tags/tag/protection), [Biological](https://cbrneworld.com/component/tags/tag/biological) ## Schema ```json { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "News", "item": "https://cbrneworld.com/news" }, { "@type": "ListItem", "position": 2, "name": "Subscribers", "item": "https://cbrneworld.com/news/subscribers" } ] } ```